TY - JOUR
T1 - Utilization of intensive behavioural treatment for obesity in patients with diabetes
AU - Kraschnewski, Jennifer
AU - Yeh, Hsin Chieh
AU - Francis, Erica
AU - Kong, Lan
AU - Lehman, Erik
AU - Rovito, Stephanie
AU - Poger, Jennifer
AU - Bryce, Cindy
N1 - Funding Information:
The study outlined in this manuscript was funded through a PCORI Award, NEN-1509-32304.
Publisher Copyright:
© 2020 World Obesity Federation
PY - 2021/2
Y1 - 2021/2
N2 - Obesity is a leading public health concern. The Centers for Medicare and Medicaid Services implemented a healthcare procedure code for intensive behavioural therapy (IBT) in 2012 to facilitate payment for addressing obesity in primary care settings, followed by universal coverage by insurers for all adults. Our objective was to understand utilization of IBT from 2009 to 2017 in patients with a diabetes diagnosis. Leveraging electronic health record data from the PaTH Clinical Data Research Network (CDRN), a partnership of six health systems, utilization of IBT was summarized at a yearly basis. The trend of IBT prevalence was examined for patients with diabetes by gender, race, age (>=65 vs <65) and rurality. A total of 205, 913 patients were included. While utilization of IBT is low (0.24% in 2017), use of IBT increased among patients with commercial insurance and Medicaid (codes S9449 and S9470) in 2011, and among patients with Medicare (code G0447) in 2012. IBT users tended to be less than 65 years of age, female, non-White (Black or Hispanic), and reside in urban areas. Overall, use of IBT in patients with diabetes remains low. Future work is necessary to understand the impact of IBT and, if effective, how to increase use within primary care.
AB - Obesity is a leading public health concern. The Centers for Medicare and Medicaid Services implemented a healthcare procedure code for intensive behavioural therapy (IBT) in 2012 to facilitate payment for addressing obesity in primary care settings, followed by universal coverage by insurers for all adults. Our objective was to understand utilization of IBT from 2009 to 2017 in patients with a diabetes diagnosis. Leveraging electronic health record data from the PaTH Clinical Data Research Network (CDRN), a partnership of six health systems, utilization of IBT was summarized at a yearly basis. The trend of IBT prevalence was examined for patients with diabetes by gender, race, age (>=65 vs <65) and rurality. A total of 205, 913 patients were included. While utilization of IBT is low (0.24% in 2017), use of IBT increased among patients with commercial insurance and Medicaid (codes S9449 and S9470) in 2011, and among patients with Medicare (code G0447) in 2012. IBT users tended to be less than 65 years of age, female, non-White (Black or Hispanic), and reside in urban areas. Overall, use of IBT in patients with diabetes remains low. Future work is necessary to understand the impact of IBT and, if effective, how to increase use within primary care.
UR - http://www.scopus.com/inward/record.url?scp=85134654079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134654079&partnerID=8YFLogxK
U2 - 10.1111/cob.12426
DO - 10.1111/cob.12426
M3 - Article
C2 - 33147654
AN - SCOPUS:85134654079
SN - 1758-8103
VL - 11
JO - Clinical obesity
JF - Clinical obesity
IS - 1
M1 - e12426
ER -